文献
J-GLOBAL ID:201802257379072412
整理番号:18A1863508
HER2陽性転移性胃または胃食道接合部癌(JACOB)に対するペルタzumab+トラスツズマブおよび化学療法:二重盲検無作為化プラセボ対照第3相試験の最終分析【JST・京大機械翻訳】
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
著者 (11件):
Tabernero Josep
(Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autonoma de Barcelona, Centro de Investigacion Biomedica en Red Cancer, Barcelona, Spain)
,
Hoff Paulo M
(Instituto do Cancer de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil)
,
Shen Lin
(Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China)
,
Ohtsu Atsushi
(Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan)
,
Shah Manish A
(Meyer Cancer Center at Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, New York, NY, USA)
,
Cheng Karen
(Product Development Oncology, Genentech Inc, South San Francisco, CA, USA)
,
Song Chunyan
(Product Development Oncology, Genentech Inc, South San Francisco, CA, USA)
,
Wu Haiyan
(Biostatistics, Biometrics, Roche Holding Ltd, Shanghai, China)
,
Eng-Wong Jennifer
(Product Development Oncology, Genentech Inc, South San Francisco, CA, USA)
,
Kim Katherine
(Product Development Oncology, Genentech Inc, South San Francisco, CA, USA)
,
Kang Yoon-Koo
(Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea)
資料名:
Lancet Oncology
(Lancet Oncology)
巻:
19
号:
10
ページ:
1372-1384
発行年:
2018年
JST資料番号:
W1266A
ISSN:
1470-2045
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)